About TALZENNA® (talazoparib) TALZENNA is an oral inhibitor of poly ADP-ribose polymerase (PARP), which plays a role in DNA damage repair. Preclinical studies have demonstrated that TALZENNA blocks ...

Eight years ago, few people had heard of transthyretin amyloid cardiomyopathy (ATTR-CM), and it was rarely diagnosed in cardiology practice. 1,2 Today, it is a treatable condition that cardiologists ...

We can't wait for you to join us! To help you prepare, we’ve created an onboarding experience that will get you ready for day one, give you an opportunity to learn more about the business, and start ...

Anaveon is a clinical-stage biopharmaceutical company, based in Switzerland, that develops biologics to modulate the function of cytokines and provide substantial therapeutic benefit to cancer ...

Technology moves fast, and there’s no better example than the rapid growth of artificial intelligence (AI). Here at Pfizer, we have long been focused on making breakthroughs that change patients’ ...

Pfizer will publish full proposals of funded initiatives, in addition to any milestone updates, interim reports, final outcomes assessments and any other relevant, pertinent data and information that ...

Pfizer Digital continuously seeks opportunities to bring fresh and innovative ideas to our business. The Digital Rotational Program is looking for recent college graduates to join our fast-paced ...

Pfizer Inc. announced today the discontinuation of the global clinical development program for bococizumab, its investigational Proprotein Convertase Subtilisin Kexin type 9 inhibitor (PCSK9i). The ...

In participants aged 12-15 years old, BNT162b2 demonstrated 100% efficacy and robust antibody responses, exceeding those reported in trial of vaccinated 16-25 year old participants in an earlier ...

-- Post-hoc, interim analysis published in Circulation: Heart Failure evaluated patients who received continuous treatment with VYNDAQEL/VYNDAMAX compared to those who first received placebo in ...

Full-Year 2024 Revenue Guidance (1) Range of $58.5 to $61.5 Billion Includes Expected Contribution from Seagen Acquisition Anticipates Approximately $8 Billion in Revenues for Comirnaty (2) and ...

Data across 45 abstracts will highlight new evidence for established medicines, including PADCEV and TALZENNA, and promising late-stage pipeline candidates such as atirmociclib and tivunatamig ...